Zinzani, P. L. Et Al. 2024. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Advances , vol.8, no.18 , 4866-4876.

Zinzani, P. L., Wang, H., Feng, J., Kim, T. M., Tao, R., Zhang, H., ... Fogliatto, L.(2024). CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. Blood Advances , vol.8, no.18, 4866-4876.

Zinzani, Pier Et Al. "CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma," Blood Advances , vol.8, no.18, 4866-4876, 2024

Zinzani, Pier L. Et Al. "CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma." Blood Advances , vol.8, no.18, pp.4866-4876, 2024

Zinzani, P. L. Et Al. (2024) . "CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma." Blood Advances , vol.8, no.18, pp.4866-4876.

@article{article, author={Pier Luigi Zinzani Et Al. }, title={CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma}, journal={Blood Advances}, year=2024, pages={4866-4876} }